2003 % (95% CI) | 2010–2011 % (95% CI) | |
---|---|---|
N=15 095 | N=12 928 | |
Overall for all smokers | 28.7 (27.9 to 29.6) | 31.1 (30.1 to 32.2) |
Type of pharmacotherapy* | ||
Varenicline (Chantix) | 0 | 10.9 (10.3 to 11.6) |
Bupropion (Zyban) | 9.1 (8.5 to 9.7) | 3.5 (3.1 to 3.8) |
Any NRT | 24.5(23.8 to 25.3) | 22.4(21.5 to 23.4) |
Patch | 17.6 (16.9 to 18.3) | 15.5 (14.8 to 16.3) |
Spray/inhaler | 2.1 (1.8 to 2.4) | 1.2 (1.0 to 1.4) |
Gum/lozenge | 10.2 (9.7 to 10.8) | 10.6 (10.0 to 11.3) |
Number of pharmacotherapies | ||
1 | 20.0 (19.3 to 20.8) | 23.0 (22.0 to 23.9) |
2 | 6.0 (5.6 to 6.4) | 6.0 (5.5 to 6.5) |
3 | 1.7 (1.5 to 2.0) | 1.6 (1.3 to 1.9) |
4+ | 1.0 (0.8 to 1.2) | 0.6 (0.4 to 0.7) |
Overall for daily smokers | 32.9 (31.9 to 34.0) | 35.7 (34.5 to 37.0) |
Type of pharmacotherapy* | ||
Varenicline (Chantix) | 0 | 12.8 (12.0 to 13.7) |
Bupropion (Zyban) | 10.8 (10.0 to 11.5) | 4.0 (3.6 to 4.5) |
Any NRT | 27.8(26.9 to 28.8) | 25.5(24.4 to 26.7) |
Patch | 20.3 (19.4 to 21.2) | 18.2 (17.3 to 19.2) |
Spray/inhaler | 2.4 (2.1 to 2.8) | 1.4 (1.1 to 1.7) |
Gum/lozenge | 11.2 (10.5 to 11.9) | 11.7 (10.9 to 12.5) |
Number of pharmacotherapies | ||
1 | 23.0 (22.0 to 23.9) | 26.2 (25.1 to 27.4) |
2 | 6.9 (6.4 to 7.5) | 6.9 (6.4 to 7.6) |
3 | 1.9 (1.6 to 2.2) | 1.8 (1.5 to 2.2) |
4+ | 1.2 (1.0 to 1.5) | 0.7 (0.5 to 0.9) |
Data source: Current Population Surveys—Tobacco Use Supplements 2003 and 2010–2011.
*If more than one therapy was used, each therapy was counted.
NRT, nicotine replacement therapy.